Title: To transform world class cancer research into new cancer treatment
1 - - To transform world class cancer research into
new cancer treatment - Jónas Einarsson, Chairman of Oslo Cancer Cluster
2Agenda
- Vision and purpose for Oslo Cancer Cluster
- OCC as an accellerator of development of new
cancer diagnostics and treatment
3 Our Vision for Oslo Cancer Cluster- Our vision
is a statement of what we aspire to, why we exist
and the impact we would like to have on society.
- To transform world class cancer research into
new cancer diagnostics and treatment and thereby
improve the lives of - cancer patients.
- We aspire to be regarded as the most innovative
cluster for cancer diagnostics and treatment in
Europe.
4 Purpose for Oslo Cancer Cluster- Our purpose
describes what we will do to achieve our vision
Through partnership between life science
industry, research institutions, university
hospitals, government and the Norwegian Cancer
Society ,the cluster will accellerate the
development of innovative cancer diagnostics and
treatment. We work to ensure access to new
treatments developed, in order to improve the
lives of cancer patients.
5Members of Oslo Cancer Cluster
- 6 Global pharma companies
- 9 Norwegian listed Biotech companies
- 16 Norwegian Start-up Biotech companies
- 7 RD facilitators
- New members Kreftforeningen and Ullevål
Universitetssykehus - Employees 1600
- Turnover 5,7 billion NOK
- RD 1,0 billion NOK
- 63 oncology projects in pipeline
6The Academic Institutions
- 2 Universities
- 4 University Hospitals
- 3 Research Institutions
- 2 Tech transfer offices
- 80 of all cancer research in Norway is
performed in these institutions
7The value creating cycle inside the cluster
8Case Innovative blood test to detect breast
cancer in its earliest stages could be made
available in 2009 - developed in the cluster in
cooperation between Radiumhospitalet and Diagenic
9Case Drug delivery system PCI Biotech developed
at Radiumhospitalet
- The PCI technology has a potential to improve the
effect both of existing drugs and of emerging
treatments such as gene therapy and other
therapies based on nanotechnology or on
biotechnological principles.
PCI is a technology for light-directed drug
delivery, used to enhance the effect of drugs by
targeted illumination of the diseased areas of
the body.
10Oslo Cancer Cluster Norwegian Centre of
Expertise
- Norway has appointed nine strong clusters
consisting of world class enterprises in their
field. Together, these clusters of excellence
make the NCE programme.The nine clusters have
been selected in strong competition with several
expert environments in Norway. - Norwegian Centres of Expertise (NCE) was launched
in 2006 aiming at strengthening innovation and
internationalisation processes in clusters based
on collaboration between companies, RD and
educational institutions and public sector. - The programme is targeted at well-established
clusters with clear strategies and a high
potential for further innovation-based growth.
The leading actors shall be a group of companies
with a long-term commitment to develop the
cluster.
Behind the NCE are SIVA, The Research Council of
Norway and Innovation Norway.
11(No Transcript)
12Agenda
- Vision and purpose for Oslo Cancer Cluster
- OCC as an accellerator of development of new
cancer diagnostics and treatment
13Strategy for Oslo Cancer Cluster - NCE
- We will transform world class cancer research
into new cancer diagnostics and treatment,
through partnership between life science
industry, research institutions, university
hospitals, government and the Norwegian Cancer
Society - Our core initiatives prioritized by our member
companies are - We will create an efficient system for clinical
trials (phase 1-3) in partnership between
university hospitals, government and the life
science industry. - We will proactively work with the government in
order to achieve internationally competitive
legislation for the life science industry in
Norway. - We will with our partners build an Innovationpark
which includes cancer research, biobanking,
cancer registry, clinical trials facility, life
science industry and high school science
education, all in the same building adjacent to
the comprehensive cancer center (CCC) at the
Norwegian Radium Hospital.
14Strategy for Oslo Cancer Cluster - NCE
- We will activate research collaborations and
innovation networks between academia and life
science industry through frequent meeting points
in Oslo Cancer Cluster. - 5. We will alongside our collaborators, work for
biotech capital development, and raise the
profile for investments in cancer diagnostics and
therapeutic companies in Norway.
15Key Performance Indicators for Oslo Cancer
Cluster
- Number of preclinical and clinical projects
- Number of clinical trials
- Number of patents
- Number of new established SME
- Workforce in the cluster
- Market value of companies locally
16 Oslo Cancer Cluster will create an efficient
system for clinical trials (phase 1-3) in
partnership between university hospitals,
government and the life science industry.
17Oslo Cancer Cluster Innovationpark
- By integrating business with research and
education, Oslo Cancer Cluster Innovation Park in
collaboration with Ullern high school, The
University of Oslo, The Norwegian Radium
Hospital, aims to create Norways leading
environment for education and innovation in the
fields of biotechnology and life sciences.
18Oslo Cancer Cluster Innovationpark
- Oslo Cancer Cluster Innovation Park (OCCI) aims
to - Fulfill development projects between university/
hospital/business - Promote innovation and creativity and support the
development of ideas into products and commercial
enterprises - Develop and support biotechnology start-up
companies through an incubator and an advisory
board
- Channel internal, external and international
financing of development projects and new
enterprises into the industrial cluster - Strengthen the training, education, specializing
and availability of competent personnel in the
fields of science, life sciences, medicine and
biotechnology
19 We will activate research collaborations and
innovation networks between academia and life
science industry through frequent meeting points
in the cluster
20.Men det er ikke alle handelsområder som
skaper ny innovasjon)